Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort

Journal of Thoracic Oncology

Volumn 10, Issue 10, 2015, Pages 1451-1457

  Gautschi, Oliver ^a   Milia, Julie ^b   Cabarrou, Bastien ^c   Bluthgen, Marie Virginia ^d   Besse, Benjamin ^d   Smit, Egbert F ^e   Wolf, Juergen ^f   Peters, Solange ^g   Früh, Martin ^h   Koeberle, Dieter ⁱ   Oulkhouir, Youssouf ^j   Schuler, Martin ^k   Curioni Fontecedro, Alessandra ^l   Huret, Benjamin ^m   Kerjouan, Mallorie ⁿ   Michels, Sebastian ^f   Pall, Georg ^o   Rothschild, Sacha ^p   Schmid Bindert, Gerald ^q   Scheffler, Matthias ^f   Veillon, Rémi ^r   Wannesson, Luciano ^s   Diebold, Joachim ^a   Zalcman, Gérard ^j   Filleron, Thomas ^c   Mazières, Julien ^b   more..

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b SERVICE DE PNEUMOLOGIE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ St Claraspital AG   (Switzerland)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m Pulmonary Department   (France)

ⁿ CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^o UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^p UNIVERSITY HOSPITAL BASEL   (Switzerland)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r HAUT LÉVÊQUE HOSPITAL   (France)

^s ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

more..

Author keywords

BRAF; Dabrafenib; Lung cancer; Targeted therapy; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; CISPLATIN DERIVATIVE; DABRAFENIB; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; SORAFENIB; VEMURAFENIB; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MULTICENTER STUDY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES;

EID: 84942515816     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000625     Document Type: Conference Paper

References (43)

1. Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 2015;26:779-786.
2. Reck M, Popat S, Reinmuth N, et al.; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 (Suppl 3):iii27-iii39.
3. Somasundaram A, Socinski MA, Burns TF. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opin Pharmacother 2014;15:2693-2708.
4. Horn L. Advances in the treatment of non-small cell lung cancer. J Natl Compr Canc Netw 2014;12(5 Suppl):764-767.
5. Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K, Rapp UR. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 1992;7:795-799.
6. Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res 2013;19:2301-2309.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
8. Wan PT, Garnett MJ, Roe SM, et al.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
9. Holderfeld M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-467.
10. Chapman PB, Hauschild A, Robert C, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
11. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
12. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-3579.
13. Kobayashi M, Sonobe M, Takahashi T, et al. Clinical signifcance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res 2011;31:4619-4623.
14. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051.
15. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532-4540.
16. Barlesi F, Blons H, Beau-Faller M, et al.; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the frst 10, 000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31 (suppl; abstr 8000).
17. Chen D, Zhang LQ, Huang JF, et al. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014;9:e101354.
18. Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol 2014;25:138-142.
19. Litvak AM, Paik PK, Woo KM, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol 2014;9:1669-1674.
20. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer 2015;121:448-456.
21. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung ade-nocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-e24.
22. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013;31:e341-e344.
23. Robinson SD, O'Shaughnessy JA, Cowey CL, Konduri K. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014;85:326-330.
24. Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2015;87:85-87.
25. Falchook GS, Long G V, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.
26. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
27. Hyman DM, Blay J Y, Chau I, et al. VE-BASKET, a frst-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). J Clin Oncol 2014;32:5s (suppl; abstr 2533)
28. Planchard D, Kim TM, Mazières J, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928). Ann Oncol 2014; 25:1-41.
29. Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003.
30. Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015;33:992-999.
31. Gautschi O, Peters S, Zoete V, et al. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 2013;82:365-367.
32. Dahlman KB, Xia J, Hutchinson K, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2:791-797.
33. Govindan R, Ding L, Griffth M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-1134.
34. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifes actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015 [Epub ahead of print].
35. Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 2013;8:e41-e42.
36. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-103.
37. Johnson GL, Stuhlmiller TJ, Angus S P, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res 2014;20:2516-2522.
38. Lin L, Asthana S, Chan E, et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci USA 2014;111:E748-E757.
39. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobi-metinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-1876.
40. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-39.
41. Joshi M, Rice SJ, Liu X, Miller B, Belani C P. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One 2015;10:e0118210.
42. Helissey C, Champiat S, Soria JC. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015;27:108-117.
43. Chen N, Fang W, Zhan J, et al. Up-regulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10:910-923.